These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 309134)

  • 21. von Willebrand factor: characterization of interaction among von Willebrand factor, ristocetin and platelet.
    Hashimoto S; Suzuki K
    Nihon Ketsueki Gakkai Zasshi; 1979 Dec; 42(6):851-63. PubMed ID: 317771
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.
    Coller BS
    J Clin Invest; 1978 May; 61(5):1168-75. PubMed ID: 307006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ristocetin-Willebrand factor activity in dog plasma.
    Johnstone IB; Lotz F
    Can J Physiol Pharmacol; 1980 Sep; 58(9):1128-34. PubMed ID: 6970064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agglutination of formalin-fixed, platelet-type von Willebrand's disease platelets by human von Willebrand factor.
    Takahashi H; Shibata A
    Thromb Haemost; 1984 Dec; 52(3):267-70. PubMed ID: 6241752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib.
    Fujimura Y; Ikeda Y; Miura S; Yoshida E; Shima H; Nishida S; Suzuki M; Titani K; Taniuchi Y; Kawasaki T
    Thromb Haemost; 1995 Aug; 74(2):743-50. PubMed ID: 8585016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tokaracetin, a new platelet antagonist that binds to platelet glycoprotein ib and inhibits von Willebrand factor-dependent shear-induced platelet aggregation.
    Kawasaki T; Taniuchi Y; Hisamichi N; Fujimura Y; Suzuki M; Titani K; Sakai Y; Kaku S; Satoh N; Takenaka T
    Biochem J; 1995 Jun; 308 ( Pt 3)(Pt 3):947-53. PubMed ID: 8948455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G.
    Moore A; Ross GD; Nachman RL
    J Clin Invest; 1978 Nov; 62(5):1053-60. PubMed ID: 309473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody nature of circulating inhibitor of plasma von Willebrand factor.
    Stratton RD; Wagner RH; Webster WP; Brinkhous KM
    Proc Natl Acad Sci U S A; 1975 Oct; 72(10):4167-71. PubMed ID: 812091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of frozen thrombocytes for the determination of von willebrand factor with the aid of ristocetin].
    Caduff T; Straub PW
    Schweiz Med Wochenschr; 1979 Mar; 109(11):399-402. PubMed ID: 34214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polybrene-induced platelet agglutination and reduction in electrophoretic mobility: enhancement by von Willebrand factor and inhibition by vancomycin.
    Coller BS
    Blood; 1980 Feb; 55(2):276-81. PubMed ID: 6766335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
    Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
    Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Support of ristocetin-induced platelet aggregation by procoagulant-inactive and plasmin-cleaved forms of human factor VIII/von Willebrand factor.
    Andersen JC; Switzer ME; McKee PA
    Blood; 1980 Jan; 55(1):101-8. PubMed ID: 6444272
    [No Abstract]   [Full Text] [Related]  

  • 33. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation.
    De Marco L; Girolami A; Russell S; Ruggeri ZM
    J Clin Invest; 1985 Apr; 75(4):1198-203. PubMed ID: 3157702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purification of porcine and human ristocetin-Willebrand factor.
    Olson JD; Brockway WJ; Fass DN; Bowie EJ; Mann KG
    J Lab Clin Med; 1977 Jun; 89(6):1278-94. PubMed ID: 405441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of porcine von Willebrand factor (platelet aggregating factor) with human platelets.
    Finlay TH; Marcus DL; Kowalski S; Silber P
    Biochim Biophys Acta; 1981 Jan; 672(1):79-88. PubMed ID: 6260227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Tuley EA; Mancuso DJ; Randi AM; Firkin BG; Howard MA; Sadler JE
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9846-9. PubMed ID: 1409710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
    Miller JL; Kupinski JM; Castella A; Ruggeri ZM
    J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
    Kao KJ; Pizzo SV; McKee PA
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5317-20. PubMed ID: 315561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
    Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.